Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz(Memorial Sloan Kettering Cancer Center), Auayporn Nademanee(City Of Hope National Medical Center), Tamás Masszi(Unified Szent István and Szent László Hospital), Edward Agura(Baylor University Medical Center), Jerzy Hołowiecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Muneer H. Abidi(Wayne State University), Andy I. Chen(Oregon Health & Science University), Patrick J. Stiff(Loyola University Medical Center), Alessandro M. Gianni(Fondazione IRCCS Istituto Nazionale dei Tumori), Angelo Michele Carella(Ospedale Policlinico San Martino), Dzhelil Osmanov(Russian Cancer Research Center NN Blokhin), Veronika Bachanová(University of Minnesota), John Sweetenham(Huntsman Cancer Institute), Anna Sureda(Institut Català d'Oncologia), Dirk Huebner(Takeda (United States)), Eric L. Sievers(Seagen (United States)), Andy Chi(Takeda (United States)), Emily K. Larsen(Seagen (United States)), Naomi Hunder(Seagen (United States)), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology)
Cited by 732Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis